Physician profile
Thomas C Hall
NPI 1174578280
$633,419.96
in general payments reported to CMS, 2019-2025
33 companies · $100K in 2025
The $100K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129K · 2020: $58K · 2021: $54K · 2022: $134K · 2023: $72K · 2024: $88K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $223K · Travel and Lodging: $19K · Food and Beverage: $12K · Consulting Fee: $3,816 · Education: $409 · Honoraria: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $223,373.12 |
| Travel and Lodging | $19,478.61 |
| Food and Beverage | $11,982.58 |
| Consulting Fee | $3,815.50 |
| Education | $409.40 |
| Honoraria | $260.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $196,163.04 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Abbvie INC. | $191,228.59 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $73,727.99 | 2019-2022 | |
| Galderma Laboratories, L.P. | $61,360.32 | 2019-2025 | Nemluvio |
| Janssen Biotech, INC. | $57,407.12 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $34,854.92 | 2019-2025 | |
| Ucb, INC. | $8,738.18 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $2,274.92 | 2021-2023 | Otezla |
| Leo Pharma INC. | $1,771.16 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $1,446.03 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,131.45 | 2019-2025 | Odomzo, Blu-U, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $524.09 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $325.70 | 2022-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $316.50 | 2019-2025 | |
| Dermavant Sciences, INC. | $314.79 | 2023-2024 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $270.76 | 2023-2025 | Zoryve |
| Incyte Corporation | $269.13 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $244.81 | 2019-2025 | |
| Allergan, INC. | $182.93 | 2020-2022 | |
| Organon LLC | $164.38 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $140.46 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Vyne Pharmaceuticals INC. | $102.13 | 2020-2021 | |
| Dermira, INC. | $85.92 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.94 | 2022-2024 | Spevigo |
| Genentech USA, INC. | $60.31 | 2019-2023 | Erivedge |
| Dusa Pharmaceuticals, INC. | $59.60 | 2019 | |
| Strata Skin Sciences, INC. | $42.44 | 2023-2025 | Xtrac |
| Kerecis Limited | $36.49 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Aclaris Therapeutics, INC. | $33.00 | 2019 | |
| Prugen, INC. Pharmaceuticals | $26.65 | 2019 | |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Celltrion USA INC. | $16.51 | 2023 | Yuflyma |
| Botanix Sb INC | $15.20 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.